Research institutes and pharmaceutical company have created a new Covid vaccine candidate in Australia’s state of Victoria, the government officials said on Wednesday adding that the clinical trials of the vaccine will begin next year.
The vaccine has been developed by Monash University researchers, pharmaceutical manufacturer IDT Australia and the Peter Doherty Institute for Infection and Immunity.
So far, the manufacturers have manufactured 450 doses of the vaccine and around 150 people will be vaccinated in the first phase of clinical trials. The companies are expected to submit its clinical trial results later in 2022.
As per the medical experts, the vaccine will provide protection against the future variants of the COVID-19.
While talking to media, Professor Colin Pouton from Monash University said that the vaccine will adjust its composition according to the virus mutations and it will help in controlling the spread of new strains of the coronavirus.
He added that the new vaccine will focus on entering the human body cells and will have the ability to boost the immunity. After getting the vaccine, the immune system will block virus from spreading into the body.
It is believed that the new composition of the vaccine will also help in providing immunity against the new Omicron variant of Covid 19.
The vaccine candidate is the Australia’s first home-grown mRNA vaccine and experts believe that once approved, the vaccine will be a significant step towards countries development as it won’t be relied on the global supply.
The government officials believe that buying vaccines from other countries is costing extra finances to Australia, even when the country has a potential to develop its own vaccines.